Drug Profile
4-Chlorokynurenine
Latest Information Update: 03 Jul 2002
Price :
$50
*
At a glance
- Originator Aventis
- Developer Nonindustrial source
- Class
- Mechanism of Action Glycine gated NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 19 Jun 1997 Preclinical development for Neurological disorders (Prevention) in USA (Unknown route)